Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is a Schedule IV controlled substance.
### Primary Indications
* Adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses may include other seizure types and anxiety disorders, though evidence and regulatory approval may vary.
### Adult Dosing
* **Lennox-Gastaut Syndrome:**
* Initiate at 5 mg twice daily.
* Titrate upwards by 5-10 mg per day weekly based on clinical response and tolerability.
* Usual maintenance dose: 10-20 mg twice daily.
* Maximum recommended dose: 20 mg twice daily (40 mg/day). Some sources suggest higher doses may be used under specialist supervision.
### Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 years and older):**
* Initiate at 5 mg once daily.
* Titrate upwards by 5-10 mg per day weekly based on clinical response and tolerability.
* Dosing should be individualized. Generally, the dose is half the adult dose for children 2 to 10 years old.
* Maximum recommended dose: 10 mg twice daily (20 mg/day) for children 2 to 10 years old. Doses up to 20 mg twice daily (40 mg/day) may be considered for patients 10 years and older.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary.
* **Renal Impairment:** Use with caution. Dose reduction may be necessary.
* **Concomitant Medications:** Consider dose reduction when used with other CNS depressants or CYP2C19 inhibitors.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
### Adverse Effects
* **Common:** Somnolence, sedation, fatigue, drooling, constipation, decreased appetite, vomiting, ataxia, irritability.
* **Serious:** Severe drowsiness, suicidal ideation/behavior, respiratory depression, dependence and withdrawal symptoms, Stevens-Johnson syndrome and toxic epidermal necrolysis (rare).
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines):** Additive CNS depression, increased risk of sedation, respiratory depression, and coma.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam levels, requiring dose reduction.
* **CYP2C19 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam levels.
* **Other Anticonvulsants:** Monitor for additive sedation or altered efficacy.
### Monitoring
* Monitor for efficacy (seizure frequency reduction).
* Monitor for adverse effects, particularly somnolence, cognitive impairment, and behavioral changes.
* Assess for signs of withdrawal upon discontinuation.
* Monitor for signs of suicidal ideation or behavior.
### Clinical Pearls
* Clobazam has a longer half-life than many other benzodiazepines, which may allow for less frequent dosing but also increase the risk of accumulation.
* Abrupt discontinuation can lead to withdrawal symptoms, including seizures. Tapering is recommended.
* Due to the risk of severe drowsiness and cognitive impairment, patients should be advised not to drive or operate heavy machinery until they know how clobazam affects them.
* Clobazam is metabolized by CYP2C19; genetic polymorphisms in this enzyme can affect drug exposure.
***
*This information is intended for clinical decision-making and does not substitute for professional judgment. Always consult the most current prescribing information and relevant clinical guidelines before initiating or modifying therapy.*
